Literature DB >> 22564354

Non-inferiority study design: lessons to be learned from cardiovascular trials.

Stuart J Head1, Sanjay Kaul, Ad J J C Bogers, A Pieter Kappetein.   

Abstract

The non-inferiority trial design has gained popularity within the last decades to compare a new treatment to the standard active control. In contrast to superiority trials, this design is complex and is based on assumptions that cannot be validated directly. Many readers and even investigators, therefore, have difficulty grasping the full methodological nature of non-inferiority trials. Non-inferiority margins are often arbitrarily chosen such that a favourable margin can bias a trial towards declaring non-inferiority. Pitfalls of non-inferiority trials are not fully appreciated, and without having identified these shortcomings, objective conclusions from non-inferiority trials cannot be made. This methodological review elaborates on what is a non-inferiority trial, why such a trial is performed, what the hazards are, and how conclusions from non-inferiority trials are derived, by providing examples of recent cardiovascular trials.

Mesh:

Year:  2012        PMID: 22564354     DOI: 10.1093/eurheartj/ehs099

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  26 in total

Review 1.  Epidemiology research in rheumatology-progress and pitfalls.

Authors:  Deborah P M Symmons
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

2.  Design and interpretation of non-inferiority studies: A clinician's perspective.

Authors:  Todd M Brown
Journal:  J Nucl Cardiol       Date:  2017-08-10       Impact factor: 5.952

Review 3.  Mitral regurgitation in patients with heart failure. Interventional therapies.

Authors:  V Rudolph; S Baldus
Journal:  Herz       Date:  2013-03       Impact factor: 1.443

4.  Including Non-inferiority Trials in Contemporary Meta-analyses of Chronic Medical Conditions: a Meta-epidemiological Study.

Authors:  Zhen Wang; Tarek Nayfeh; Nigar Sofiyeva; Oscar J Ponte; Rami Rajjoub; Konstantinos Malandris; Mohamed Seisa; Haitao Chu; Mohammad Hassan Murad
Journal:  J Gen Intern Med       Date:  2020-04-21       Impact factor: 5.128

Review 5.  Individual and composite study endpoints: separating the wheat from the chaff.

Authors:  Robert Goldberg; Joel M Gore; Bruce Barton; Jerry Gurwitz
Journal:  Am J Med       Date:  2014-01-28       Impact factor: 4.965

6.  Cardiopulmonary benefits of reducing indoor particles of outdoor origin: a randomized, double-blind crossover trial of air purifiers.

Authors:  Renjie Chen; Ang Zhao; Honglei Chen; Zhuohui Zhao; Jing Cai; Cuicui Wang; Changyuan Yang; Huichu Li; Xiaohui Xu; Sandie Ha; Tiantian Li; Haidong Kan
Journal:  J Am Coll Cardiol       Date:  2015-06-02       Impact factor: 24.094

7.  Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials.

Authors:  Behnood Bikdeli; César Caraballo; John Welsh; Joseph S Ross; Sanjay Kaul; Gregg W Stone; Harlan M Krumholz
Journal:  Clin Trials       Date:  2020-08-24       Impact factor: 2.486

8.  A Clinical Comparison of Intravenous and Epidural Local Anesthetic for Major Abdominal Surgery.

Authors:  Abdullah S Terkawi; Siny Tsang; Ali Kazemi; Steve Morton; Roy Luo; Daniel T Sanders; Lindsay A Regali; Heather Columbano; Nicole Y Kurtzeborn; Marcel E Durieux
Journal:  Reg Anesth Pain Med       Date:  2016 Jan-Feb       Impact factor: 6.288

Review 9.  Antimicrobial Treatment Duration in Sepsis and Serious Infections.

Authors:  Lindsay M Busch; Sameer S Kadri
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

10.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.